tradingkey.logo
๎™ผ
tradingkey.logo
๎™๊ฒ€์ƒ‰
๎™

Akoustis Technologies Ord Shs

AKTS
๎˜ญ๊ด€์‹ฌ ๋ชฉ๋ก์— ์ถ”๊ฐ€
28.357USD
+1.347+4.99%
์‹œ์žฅ ์šด์˜ ์‹œ๊ฐ„ย ๏ผˆET๏ผ‰์‹œ์„ธ๋Š” 15๋ถ„ ์ง€์—ฐ๋ฉ๋‹ˆ๋‹ค
1.51B์‹œ๊ฐ€์ด์•ก
์†์‹คP/E TTM
์ƒ์„ธ ์ฐจํŠธ ๋ณด๊ธฐ
TradingKey ๅ›พ่กจ
Intraday
1m
30m
1h
D
W
M
D

์˜ค๋Š˜

+4.99%

5์ผ

+25.31%

1๊ฐœ์›”

+39.41%

6๊ฐœ์›”

0.00%

์˜ฌํ•ด ํ˜„์žฌ๊นŒ์ง€

0.00%

1๋…„

0.00%

ํ•ต์‹ฌ ์ˆ˜์น˜
27.210์‹œ๊ฐ€
28.725์ตœ๊ณ ๊ฐ€
197.85K๊ฑฐ๋ž˜๋Ÿ‰
์†์‹คP/E TTM
์†์‹ค๋™์  P/E ๋น„์œจ
--๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
0.37%ํšŒ์ „์œจ
27.010์ „์ผ ์ข…๊ฐ€
26.160์ตœ์ €๊ฐ€
3.78M๋งค์ถœ์•ก
์†์‹ค์ฃผ๊ฐ€์ˆ˜์ต๋น„์œจ
2.99P/B
0.00%๋ฐฐ๋‹น ์ˆ˜์ต๋ฅ 
-167.18%ROA
29.16052์ฃผ ์ตœ๊ณ ๊ฐ€
0.67๊ฑฐ๋ž˜๋Ÿ‰ ๋น„์œจ
-167.95M์ˆœ์ด์ต
53.40M์ฃผ์‹
-1.3392์ฃผ๋‹น์ˆœ์ด์ต
--๋ฒ ํƒ€
-11970.59%ROE
14.72052์ฃผ ์ตœ์ €๊ฐ€
9.50%๋ณ€๋™ ํญ
100.00%์ด ์ด์ต๋ฅ 
1.51B์‹œ๊ฐ€์ด์•ก
7.55๋ณด์ƒ/์œ„ํ—˜
4.34%์œ„ํ—˜๋ฅ 

TradingKey Akoustis Technologies Ord Shs ์ฃผ์‹ ์ ์ˆ˜๎˜

ํ†ตํ™”: USD ๋งˆ์ง€๋ง‰ ์—…๋ฐ์ดํŠธ: 2026-06-23

์ฃผ์š” ์ธ์‚ฌ์ดํŠธ

Akoustis Technologies Ord Shs์˜ ํŽ€๋”๋ฉ˜ํ„ธ์€ ๋น„๊ต์  ์•„์ฃผ ๊ฑด์ „ํ•œ ์ƒํƒœ์ด๋ฉฐ, ์„ฑ์žฅ ์ž ์žฌ๋ ฅ์€ ๋†’์Šต๋‹ˆ๋‹ค.๊ธฐ์—…์˜ ๋ฐธ๋ฅ˜์—์ด์…˜์€ ์ ์ •ํ•˜๊ฒŒ ํ‰๊ฐ€๋œ ๊ฒƒ์œผ๋กœ ๊ฐ„์ฃผ๋˜๋ฉฐ, ํˆฌ์ž ํ™€๋”ฉ ํšŒ์‚ฌ ์‚ฐ์—…์—์„œ 12๊ฐœ ์ค‘ 6์œ„ ๋žญํ‚น.๊ธฐ๊ด€ ๋ณด์œ  ๋น„์œจ์€ ๋งค์šฐ ๋†’์€.์ง€๋‚œ ํ•œ ๋‹ฌ ๋™์•ˆ ์—ฌ๋Ÿฌ ์• ๋„๋ฆฌ์ŠคํŠธ๊ฐ€ ํ•ด๋‹น ๊ธฐ์—…์„ ๊ฐ•๋ ฅ ๋งค์ˆ˜(์œผ)๋กœ ํ‰๊ฐ€ํ–ˆ์œผ๋ฉฐ, ์ตœ๊ณ  ๋ชฉํ‘œ ๊ฐ€๊ฒฉ์€ 35.50์ž…๋‹ˆ๋‹ค.์ค‘๊ธฐ์ ์œผ๋กœ ์ฃผ๊ฐ€๋Š” ์ƒ์Šน ์ถ”์„ธ์ผ ๊ฒƒ์œผ๋กœ ์˜ˆ์ƒ๋ฉ๋‹ˆ๋‹ค.์ง€๋‚œ ํ•œ ๋‹ฌ๊ฐ„ ์ฃผ์‹ ์‹œ์žฅ์—์„œ ํƒ์›”ํ•œ ์„ฑ๊ณผ๋ฅผ ๊ฑฐ๋‘๊ณ  ์šฐ์ˆ˜ํ•œ ํŽ€๋”๋ฉ˜ํ„ธ์„ ๊ธฐ๋กํ–ˆ์ง€๋งŒ, ๊ธฐ์ˆ ์  ์ง€ํ‘œ๊ฐ€ ํ˜„์žฌ์˜ ์ถ”์„ธ๋ฅผ ๋’ท๋ฐ›์นจํ•˜์ง€ ๋ชปํ•˜๊ณ  ์žˆ์Šต๋‹ˆ๋‹ค.์ฃผ๊ฐ€๋Š” ์ง€์ง€์„ ๊ณผ ์ €ํ•ญ์„  ์‚ฌ์ด์—์„œ ํšก๋ณดํ•˜๊ณ  ์žˆ์œผ๋ฉฐ, ๋ฒ”์œ„ ๋งค๋งค ๊ธฐ๋ฐ˜์˜ ์Šค์œ™ ํŠธ๋ ˆ์ด๋”ฉ์— ์ ํ•ฉํ•œ ์ƒํ™ฉ์ž…๋‹ˆ๋‹ค.

Akoustis Technologies Ord Shs ์ ์ˆ˜๎˜ฐ๎˜ฐ

๊ด€๋ จ ์ •๋ณด

์‚ฐ์—… ์ˆœ์œ„
6 / 12
์ „์ฒด ์ˆœ์œ„
377 / 4573
์‚ฐ์—…
ํˆฌ์ž ํ™€๋”ฉ ํšŒ์‚ฌ

์ €ํ•ญ์„  & ์ง€์ง€์„ 

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

๋ ˆ์ด๋” ์ฐจํŠธ

ํ˜„์žฌ ๊ฐ€๊ฒฉ
๊ณผ๊ฑฐ

๋ฏธ๋””์–ด ๋ณด๋„

์ตœ๊ทผ 24 ์‹œ๊ฐ„
๋ณด๋„ ์ˆ˜์ค€

๋งค์šฐ ๋‚ฎ์€
๋งค์šฐ ๋†’์€
๊ธ์ •+

Akoustis Technologies Ord Shs ์ฃผ์š” ๋‚ด์šฉ

๊ฐ•์ ์œ„ํ—˜ ์š”์†Œ
Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
์„ฑ์žฅ ์ค‘
ํšŒ์‚ฌ๋Š” ์„ฑ์žฅ ๋‹จ๊ณ„์— ์žˆ์œผ๋ฉฐ, ์ตœ์‹  ์—ฐ๊ฐ„ ์ˆ˜์ต์€ ๋ฏธํ™” 6.50M์— ๋‹ฌํ•ฉ๋‹ˆ๋‹ค.
๊ณผ์†Œ ํ‰๊ฐ€๋œ
ํšŒ์‚ฌ์˜ ์ตœ์‹  PE์€ -20.17๋กœ, ์ตœ๊ทผ 3๋…„ ๊ธฐ์ค€ ๋‚ฎ์€ ๋ฐฑ๋ถ„์œ„ ๋ฒ”์œ„์— ์†ํ•ฉ๋‹ˆ๋‹ค.
๊ธฐ๊ด€ ๋งค์ˆ˜
์ตœ์‹  ๊ธฐ๊ด€ ๋ณด์œ  ์ฃผ์‹ ์ˆ˜๋Š” 27.52M์ฃผ์ด๋ฉฐ, ์ „ ๋ถ„๊ธฐ ๋Œ€๋น„ 3.93% ์ฆ๊ฐ€ํ–ˆ์Šต๋‹ˆ๋‹ค.

๋ถ„์„๊ฐ€ ๋ชฉํ‘œ๊ฐ€

7 ๋ช…์˜ ๋ถ„์„๊ฐ€๋ฅผ ๊ธฐ์ค€์œผ๋กœ
๊ฐ•๋ ฅ ๋งค์ˆ˜
ํ˜„์žฌ ๋“ฑ๊ธ‰
35.500
๋ชฉํ‘œ ๊ฐ€๊ฒฉ
+43.20%
์ƒ์Šน ์—ฌ๋ ฅ
๋ฉด์ฑ… ์กฐํ•ญ: ์• ๋„๋ฆฌ์ŠคํŠธ ํ‰๊ฐ€ ๋ฐ ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” ์ •๋ณด ์ œ๊ณต์„ ์œ„ํ•œ ๋ชฉ์ ์œผ๋กœ LSEG์—์„œ ์ œ๊ณต๋˜๋ฉฐ, ํˆฌ์ž ์กฐ์–ธ์œผ๋กœ ๊ฐ„์ฃผ๋˜์ง€ ์•Š์Šต๋‹ˆ๋‹ค.

Akoustis Technologies Ord Shs ๋‰ด์Šค

๋” ๋งŽ์€ ๋‰ด์Šค๊ฐ€ ๊ณง ์—…๋ฐ์ดํŠธ๋ฉ๋‹ˆ๋‹ค. ๊ณ„์† ์ง€์ผœ๋ด ์ฃผ์„ธ์š”โ€ฆ

์žฌ๋ฌด ์ง€ํ‘œ๎˜

EPS

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

์ด ์ˆ˜์ต

๊ธฐ์—…์ด ์•„์ง ๊ด€๋ จ ๋ฐ์ดํ„ฐ๋ฅผ ๊ณต๊ฐœํ•˜์ง€ ์•Š์•˜์Šต๋‹ˆ๋‹ค.

Akoustis Technologies Ord Shs ์ •๋ณด๎˜

Aktis Oncology Inc is a United States-based biotechnology company. The Company focuses on developing targeted radiopharmaceuticals for treating solid tumor cancers. It also aims to deliver high doses of radiation directly to tumors, minimizing harm to healthy tissue. It transforms cancer care with novel platform technologies that enables to design and develop precision for radiopharmaceuticals. Its drugs are designed to bind to specific proteins on cancer cells, delivering radiation directly to the tumor.
์ข…๋ชฉ ์ฝ”๋“œ AKTS
ํšŒ์‚ฌAkoustis Technologies Ord Shs
CEORoden (Matthew)
์›น์‚ฌ์ดํŠธhttps://www.aktisoncology.com/

์ž์ฃผ ๋ฌป๋Š” ์งˆ๋ฌธ

Akoustis Technologies Ord Shs(AKTS)์˜ ํ˜„์žฌ ๊ฐ€๊ฒฉ์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Akoustis Technologies Ord Shs(AKTS)์˜ ํ˜„์žฌ ์ฃผ๊ฐ€๋Š” 27.01์ž…๋‹ˆ๋‹ค.

Akoustis Technologies Ord Shs์˜ ์ข…๋ชฉ ๊ธฐํ˜ธ(Symbol)๋Š” ๋ฌด์—‡์ธ๊ฐ€์š”?

๎™Œ
Akoustis Technologies Ord Shs์˜ ์ข…๋ชฉ ์ฝ”๋“œ๋Š” AKTS์ž…๋‹ˆ๋‹ค.

Akoustis Technologies Ord Shs์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Akoustis Technologies Ord Shs์˜ 52์ฃผ ์ตœ๊ณ ๊ฐ€๋Š” 29.16์ž…๋‹ˆ๋‹ค.

Akoustis Technologies Ord Shs์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Akoustis Technologies Ord Shs์˜ 52์ฃผ ์ตœ์ €๊ฐ€๋Š” 14.72์ž…๋‹ˆ๋‹ค.

Akoustis Technologies Ord Shs์˜ ์‹œ๊ฐ€์ด์•ก์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Akoustis Technologies Ord Shs์˜ ์‹œ๊ฐ€์ด์•ก์€ 1.32B์ž…๋‹ˆ๋‹ค.

Akoustis Technologies Ord Shs(AKTS)์˜ ํ˜„์žฌ ํˆฌ์ž ๋“ฑ๊ธ‰์€ ๋งค์ˆ˜, ๋ณด์œ , ๋งค๋„ ์ค‘ ์–ด๋–ค๊ฐ€์š”?

๎™Œ
์• ๋„๋ฆฌ์ŠคํŠธ๋“ค์— ๋”ฐ๋ฅด๋ฉด, Akoustis Technologies Ord Shs(AKTS)๋Š” ์ „๋ฐ˜์ ์ธ ํ‰๊ฐ€์—์„œ STRONG BUY ๋“ฑ๊ธ‰์„ ๋ฐ›๊ณ  ์žˆ์œผ๋ฉฐ, ๋ชฉํ‘œ ์ฃผ๊ฐ€๋Š” 35.50์ž…๋‹ˆ๋‹ค.

Akoustis Technologies Ord Shs(AKTS)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ ์–ผ๋งˆ์ธ๊ฐ€์š”?

๎™Œ
Akoustis Technologies Ord Shs(AKTS)์˜ ์ฃผ๋‹น์ˆœ์ด์ต(EPS TTM)์€ -1.26์ž…๋‹ˆ๋‹ค.
KeyAI
๎™